更新于：2024-06-22

Hydrochlorothiazide

氢氯噻嗪

更新于：2024-06-22

概要

概要

基本信息

简介氢氯噻嗪是一种小分子药物，作用于噻嗪类敏感氯化钠协同转运蛋白，是噻嗪类敏感氯化钠协同转运蛋白抑制剂。它的适应症包括尿崩症、水肿、高血压和肾结石等。氢氯噻嗪最初由诺华制药公司研发，并于1959年2月12日获得首次批准。该药物通过抑制NCC，减少肾脏中的钠重吸收，从而促进尿液排泄和水分排出，达到利尿的效果。此外，它还可以降低血压和防止肾结石形成。虽然氢氯噻嗪可以缓解症状，但也存在一些不良反应，如低钾血症、头晕、乏力等，需要在医生的指导下使用。总体而言，氢氯噻嗪是一种常用的利尿药和降压药，对多种疾病的治疗具有重要作用。

药物类型

小分子化药

别名

HCTZ、Hydrochlorothiazide (JP17/USP/INN)、氢氯噻嗪微片

+ [8]

靶点

NCC

作用机制

NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂)

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [2]

在研适应症

非在研适应症

原研机构

在研机构

+ [2]

非在研机构

Novartis AG

Novartis Pharmaceuticals Corp.

最高研发阶段批准上市

首次获批日期

美国 (1959-02-12),

高血压

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C7H8ClN3O4S2

InChIKeyJZUFKLXOESDKRF-UHFFFAOYSA-N

CAS号58-93-5

关联

248

项与氢氯噻嗪相关的临床试验

NCT05917275 / Recruiting临床4期

Multi-Omics to Predict the Blood Pressure Response to Antihypertensives

The goal of this clinical trial is to develop biomarkers composed of multiple OMICs (MOMICs) for prediction of blood pressure response to antihypertensive drugs in the treatment of primary hypertension. The main objectives are:
Primary objective:
- To identify MOMICs biomarkers that predict the response in 24-hour blood pressure to antihypertensive treatment for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine)
Secondary objectives:
To identify a MOMICs biomarker that predict the response in night-time blood pressure to anti-hypertensive treatment for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine)
To identify MOMICs biomarkers that predict side effects, including changes in QoLof olmesartan, amlodipine and hydrochlorothiazide.
Exploratory objective:
To assess changes in MOMICs biomarkers induced by each drug
Participants will undergo three 4-week treatment periods:
Each subject receives 3 out of 4 possible treatments (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine).
Before and after each treatment period OMICS measurements and an ABPM are performed.
At the end of each treatment period blood is sampled for drug level testing to assess adherence.
Electrolytes and kidney function are checked 5-7 days after start of each treatment period.

开始日期2024-04-04

申办/合作机构

Radboud University Medical Center

NCT06111885 / Not yet recruiting临床2期

Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention

The aim of this study is to test the efficacy of the two long-acting thiazide-like diuretics indapamide and chlorthalidone in reducing urine supersaturation for calcium oxalate and calcium phosphate compared to the short-acting thiazide diuretic hydrochlorothiazide for the prevention of calcium-containing kidney stones.

开始日期2024-04-01

申办/合作机构

Insel Gruppe AG

[+1]

NCT05443932 / Not yet recruiting临床4期IIT

Dapagliflozin and Hydrochlorothiazide Treatment in Recurring Kidney Stone Patients - a Randomised Single Center Cross-over Study

Current prevention strategies in patients with recurrence of kidney stones show especially in high-risk patients a diversely and in the long-term not successful outcome in a sustainable number of cases. Recent studies have revealed that Dapagliflozin has the potential to decrease risk and incidence of urolithiasis events especially in patients suffering from Diabetes. The investigators propose that Dapagliflozin has the potential to increase the metabolic situation of hyperoxaluric patients with recurrence of urolithiasis. The investigators therefore test whether Dapagliflozin can decrease the oxalate excretion compared to the current strategy with Hydrochlorothiazide. The study may open up a new way of preventing urolithiasis in patients with high-risk of recurring urolithiasis.

开始日期2024-03-04

申办/合作机构

Medical University of Vienna

100 项与氢氯噻嗪相关的临床结果

登录后查看更多信息

100 项与氢氯噻嗪相关的转化医学

登录后查看更多信息

100 项与氢氯噻嗪相关的专利（医药）

登录后查看更多信息

7,419

项与氢氯噻嗪相关的文献（医药）

2024-03-01·Journal of hypertension

Use trends of chlorthalidone and hydrochlorothiazide among United States adults with hypertension: National Health and Nutrition Examination Survey 2009–2018

Article

作者: Perez, Alexandra ; El-Mcharfie, Layall ; Puchades, Emily ; Hale, Genevieve ; Jacomino, Gema

Objectives::

To estimate the national prevalence of chlorthalidone and hydrochlorothiazide use among adults diagnosed with hypertension by sociodemographic subgroup, healthcare access status, and clinical factors.

Methods::

Data was extracted from the National Health and Nutrition Examination Survey for 2009–2010 through 2017–2018 survey waves. Patients at least 20 years old, diagnosed with hypertension, and on hydrochlorothiazide or chlorthalidone were included. Uni-variable logistic regression models estimated the odds of being on chlorthalidone compared with hydrochlorothiazide use by sociodemographic and clinical factors. Analyses were adjusted for multi-stage complex survey design and are nationally representative.

Results::

Two thousand five hundred and eighty-five participants were included with 95.2% participants using hydrochlorothiazide and 4.8% using chlorthalidone. Participants over 65 years were more likely to be on chlorthalidone compared with younger counterparts [odds ratio (OR) 1.8; 95% confidence interval (CI) 1.12–2.88]. Participants with hypokalemia (OR 2.62; 95% CI 1.56–4.42) or hyponatremia [OR 2.298; 95% CI 1.23–4.30) were more likely to be using chlorthalidone compared with patients with normal levels.

Conclusion::

Chlorthalidone, a potent and effective first-line antihypertensive agent and thoroughly studied thiazide diuretic with substantial cardiovascular benefits, continues to be underutilized in patients with hypertension. Findings demonstrated that individuals receiving chlorthalidone were more likely to be 65 years or older and to experience hyponatremia or hypokalemia. Sociodemographic factors, healthcare access and use, clinical factors, and medical conditions did not appear to sway the choice in thiazide diuretic use.

2024-02-01·Clinical pharmacology in drug development

Pharmacokinetic and Bioequivalence Study of Lisinopril/Hydrochlorothiazide Tablet Under Fasting and Postprandial Conditions in Healthy Chinese Subjects

Article

作者: Chen, Lu ; Li, Na ; Zhang, Qian ; Li, Qin ; Xiong, Yun ; Chen, Jiyu ; Liu, Shijing ; He, Yan ; Zhou, Yan ; Zeng, Yan ; Yang, Zhuan ; Liu, Lin ; Du, Peng ; Mi, Xiaolan ; Zeng, Chen ; Ze, Qiuyuan

Abstract:

The objective of this research was to evaluate and compare the pharmacokinetic profiles and safety of lisinopril/hydrochlorothiazide (10 mg/12.5 mg) tablets in the test and reference formulations administered to participants in both fasting and postprandial states and to evaluate the bioequivalence of the 2 products in healthy Chinese volunteers. This study employed a single‐center, randomized, open‐label, single‐dose dosing trial involving a cumulative 96 healthy adult participants (60 in the fasting group and 36 in the postprandial group). Each group comprised 2 sequence sets, and a 2‐week washout period was implemented. There were no statistically significant differences in time to maximum concentration and terminal elimination half‐life between the test and control groups under fasting and postprandial conditions (P > .05), and the 90% CIs for area under the plasma concentration–time curve and maximum plasma concentration were within the bioequivalence range of 80%‐125%. Pharmacokinetic results indicate a large food effect for lisinopril, meaning that there is a loss of approximately 20%‐25% of systemic exposure from fasting to postprandial administration for both preparations. The study demonstrated that a single oral dose of generic lisinopril/hydrochlorothiazide is bioequivalent to the reference product and well tolerated, with no significant adverse events observed, and that both products are similarly safe in a cohort of healthy Chinese male and female participants, following administration under fasting and postprandial conditions.

2024-01-27·The Journal of pharmacy and pharmacology

3-Demethyl-2-geranyl-4-prenylbellidifoline, a natural xanthone with diuretic and kidney protective properties

Article

作者: Filho, Valdir Cechinel ; Niero, Rivaldo ; Mariano, Luísa Nathália Bolda ; de Souza, Priscila ; Boeing, Thaise ; da Silva, Luisa Mota

Abstract:

Objectives:

The diuretic and kidney protective effect of the 3-demethyl-2-geranyl-4-prenylbellidifoline (DGP) were evaluated in rats.

Methods:

The normotensive (NTR) and spontaneously hypertensive rats (SHR) received, once a day for 7 days, oral treatment with DGP (0.1 mg/kg), hydrochlorothiazide (10 mg/kg), or vehicle (10 ml/kg). Urine, blood, and kidney samples were collected for further analysis.

Key findings:

The urine and Na+ elimination content were significantly higher in the groups that received DGP. Furthermore, a Ca2+-sparing action was detected in the urine of DGP-treated groups, which was consistent with the reduction in calcium oxalate crystal formation. Relevantly, the treatment did not change the parameters examined in the blood. Concerning the renal analyses, DGP treatment recovered the morphological damages of the kidney corpuscle area of SHR. In addition to the differences observed between the NTR and SHR vehicle groups, DGP augmented the amount of reduced glutathione and the activity of glutathione S-transferase GST while reducing the catalase and N-acetyl-β-D-glucosaminidase activity and nitrite levels.

Conclusion:

Together, this study displayed the prolonged diuretic action of DGP and its natriuretic, Ca2+-sparing, and antiurolytic effects. The antioxidative and anti-inflammatory effects of DGP were evidenced in SHR kidneys, opening perspectives for further studies regarding the benefits of this xanthone.

项与氢氯噻嗪相关的新闻（医药）

2024-06-17

·drugs

2008 to 2021 Saw Increase in Prevalence of Chronic HTN in Pregnancy

MONDAY, June 17, 2024 -- For pregnant individuals, the prevalence of chronic hypertension more than doubled between 2008 and 2021, according to a study published online June 17 in Hypertension . Stephanie A. Leonard, Ph.D., from the Stanford University School of Medicine in California, and colleagues analyzed commercial insurance claims from 2007 to 2021 and assessed the prevalence of chronic hypertension during pregnancy and trends in oral antihypertensive medication use. The researchers found that between 2008 and 2021, the prevalence of chronic hypertension increased steadily from 1.8 to 3.7 percent among 1,900,196 pregnancies. During the study period, antihypertensive medication use among those with chronic hypertension was relatively stable (57 to 60 percent). There was a decrease seen in the proportion of pregnant individuals with chronic hypertension treated with methyldopa or hydrochlorothiazide (from 29 to 2 percent and from 11 to 5 percent, respectively), and there was an increase seen in the proportion treated with labetalol or nifedipine (from 19 to 42 percent and from 9 to 17 percent, respectively). Following the 2017 American College of Cardiology and American Heart Association hypertension guidelines, there was no change observed in the prevalence or treatment of chronic hypertension during pregnancy. "There were large shifts in the medications used to treat chronic hypertension in pregnancy, with labetalol supplanting methyldopa as the most commonly used antihypertensive medication," the authors write. One author disclosed ties to the pharmaceutical industry.

AHA会议临床研究

2024-06-04

·E药经理人

突发！GSK市值蒸发580亿元，7万起未决诉讼再起波澜。被致癌物超标胃药“锁喉”，何解？

一款全球热销胃药，因含致癌物超标3000倍而被下架、召回，还让赛诺菲、辉瑞花费25亿元解决14000多起诉讼。但诉讼麻烦远未结束，多达7万多起案件近日允许继续审理，“砸”向原研厂商GSK。GSK或将支付20亿美元解决索赔，其市值连夜缩水80多亿美元…… 撰文| 润屿编辑| 顿河芳晨 “我因服用非处方Zantac，患上食道癌”“Zantac药物标签上并未正确警告公众有患癌风险”“Zantac设计存在缺陷”“因Zantac，我的当事人被诊断出膀胱癌”……超75000起针对GSK胃灼热治疗药物Zantac（雷尼替丁，商品名善胃得）的诉讼，再次让这家处于艰难调整期的MNC，高度紧张了起来。 6月3日，GSK美股股价暴跌近9%，创下2022年年中以来最大跌幅，市值缩水超80亿美元（约580亿元人民币）。美国特拉华州法官Vivian Medinilla作出一项重要裁决：批准超过七万起针对Zantac的诉讼（指控该药物致癌）继续审理，并进入陪审团审判，陪审团可以听取专家对Zantac造成的潜在健康风险分析。有业内人士称，GSK可能要掏出20亿美元，约145亿元人民币，才能解决索赔。 GSK上一次股价暴跌在2022年，同样与Zantac诉讼案有关。自2019年Zantac卷入致癌风波被召回后，GSK、赛诺菲、辉瑞等Zantac生产制造商深受诉讼困扰，已经力砸数笔高昂的裁决、和解及诉讼费用。据外媒报道，年初，GSK曾处理了多起诉讼案件，但没想到，更大的麻烦还在后面。虽然诉讼很少为MNC带来真正的商业风险，但会影响资本市场的表现，深陷“除草剂致癌”案件的拜耳，以及备受滑石粉争议的强生，曾经就处于这样的困境当中。 2A类致癌物超标，“Zantac诉讼”逼疯GSK们善胃得（Zantac）曾经是风靡一时的老药，由GSK研制，在1983年上市销售（处方药）。1995年，GSK推出Zantac 75毫克制剂的非处方药版本。1998年，辉瑞获得Zantac非处方药权利，并在2004年推出了Zantac 150毫克制剂。2006年，BI收购了Zantac在美国的OTC权利。 2017年，赛诺菲与BI宣布签署业务互换协议，BI将其消费者保健业务换给赛诺菲，Zantac由此过渡给赛诺菲。当时，尽管市场对Zantac杂质已有一定怀疑声音，但赛诺菲坚称Zantac是安全的。多年来，Zantac作为处方药和非处方药，被这四家MNC进行销售。上市前几年，基于用药依从性较好、副作用较少等优势，以及较为巧妙的定价策略，Zantac卖得非常好，上市第三年销售额就超过了20亿美元。 2017年，一种名为N-亚硝基二甲胺（NDMA）的物质被国际致癌研究机构列为“2A类致癌物”。2019年，Zantac被发现在其活性成分雷尼替丁中具备“不可接受的N-亚硝基二甲胺水平”，由此被要求停售。 2020年，美国FDA进一步确定，放置时间越久，或越在高于室温的条件下储存，Zantac中的NDMA含量就会越大，存在NDMA超标风险。FDA再度告诉所有生产制造商，停止在美国销售用雷尼替丁制成的Zantac。随后，其他数十个国家和司法管辖区也通过发布禁令、召回或警告，来应对NDMA风险。发现NDMA问题之后，科学界积极探索雷尼替丁与癌症之间的联系，但同时，Zantac的召回和市场退出也导致了数千人对GSK、辉瑞、赛诺菲和BI等制造商提起诉讼，且诉讼量愈发庞大。仅在2020年，GSK就参与了大约1200起 Zantac诉讼。参与“Zantac诉讼”的人，一般具备以下条件：被诊断出患癌之前，服用 Zantac 至少一年。被诊断出患有膀胱癌、胃癌、食道癌、肝癌或胰腺癌。首次诊断癌症时年龄在89岁以下。每周至少使用 Zantac 一次，持续一年或更长时间。而针对Zantac诉讼的主要主张为，制药商未能充分警告公众该产品的活性成分雷尼替丁不稳定，可以在胃中形成NDMA，反过来导致患癌的风险增加。 2022年，Zantac诉讼风波发酵至高潮。尽管GSK发布声明，称FDA和欧洲药品管理局（EMA）经调查，已经得出结论，并没有证据表明雷尼替丁治疗与癌症发展之间存在因果关系，但数千起诉讼案件仍旧引发投资者质疑。2022年8月，GSK、赛诺菲股价纷纷大跌。制造商们采取的积极抗辩，在当时让诉讼短暂迎来反转。佛罗里达州一地区法官驳回了原告关于Zantac导致多种癌症的科学证据，并表示原告向联邦法院提起的近2500起诉讼证据是有缺陷的，无法证明致癌风险。对此，GSK、赛诺菲的股价才有所回升。然而，这不代表事情结束，反而在无形之中愈演愈烈。在当时，佛罗里达州联邦法院还有2000多起未决诉讼，州法院还有数百起诉讼案件。到了2024年6月，有数据显示，美国佛罗里达州南区地方法院的多区诉讼（MDL）中有超14000起Zantac诉讼待决。据了解，GSK在2024年初曾处理过多起案件。另有海外媒体称，今年以来，赛诺菲和辉瑞已提供高达3.5亿美元，以解决超过14000起Zantac诉讼。而最新的消息显示，超75000起诉讼案件压力将继续压在GSK、辉瑞、赛诺菲和BI身上，作为最早生产制造销售该药的GSK，无疑承载了最大的风险。召回、停售、退市，被“神药”坑了的药企对于最新的裁决，GSK立即发布了公告回应。 GSK在公告中摆明了强硬态度：不同意这样的裁决方式，并将立即向特拉华州最高法院寻求上诉。GSK要求驳回动议，并要求提出额外的辩护、案件的分割和索赔人的使用证明，此外，GSK还将进入个别案件审判阶段。并且，GSK再次向业内强调：科学界的共识是，没有一致或可靠的证据表明雷尼替丁会增加患任何癌症的风险，允许索赔的裁决与2022年12月联邦法院在同一法律标准下的多区诉讼（MDL）裁决相矛盾。接下来，GSK将继续积极捍卫自己免受所有索赔。 Zantac诉讼，到底会迎来什么样的结局，何时迎来终局，目前看来似乎还要在非常漫长的时间之后才可知晓。但深陷诉讼中的药企，要付出实际的资金及经历去应付，而一点风吹草动，在资本市场上带来的就是股价波动。不得不提，现在是GSK调整的关键时期，亟待提振业绩，也亟需看到调整成效，GSK投资者也需要看到更多信心。但此次股价应声大跌背后，有不少投资者质疑：从Zofran，到质子泵抑制剂，帕西罗汀，再到Zantac，因产品问题陷入“起诉门”的，为什么老是GSK？此外，因药品生产质量问题，GSK不止一次被推上风口浪尖。例如在2022年，NMPA发现GSK对出口中国的度他雄胺软胶囊未按照注册标准进行逐批、全项检验，且在微生物污染风险防控方面存在不足，对此，国家药监局决定立即暂停进口、销售、使用这款药物。而说回Zantac诉讼本身的“罪魁祸首”——N-亚硝基二甲胺（NDMA），其实，Zantac并不是唯一因NDMA污染而被召回的药物，此前，缬沙坦、氯沙坦和二甲双胍等产品，就因一些批次中因这类物质检测呈阳性，而被召回。 2018年，缬沙坦和氯沙坦钾因为杂质问题，而震动了整个制药行业。其中，一家本土大型药企，也因此深处于舆论漩涡。欧洲药品管理局在当时发出通告：在评估浙江华海生产的缬沙坦原料药药品过程中，检测出杂质，部分缬沙坦药品被欧盟予以召回，而检测出的杂质正是亚硝基二甲胺。召回公告发布后，德国、意大利、芬兰、奥地利、日本等多个国家药监部门相继发布召回公告。此事一经报道，立刻在国内引起巨大关注，华海股价也一度下跌10%。此后，华海药业立即主动暂停了市场供应。同年11月，山德士发布产品召回公告，宣布在美国召回一批氯沙坦氢氯噻嗪片，原因是氯沙坦钾原料药中含有杂质亚硝基二乙胺（NDEA），NDEA同样被国际癌症研究机构归类为2A级可能的人类致癌物。 2020年5月，FDA发文，称发现在一些二甲双胍缓释制剂中的NDMA含量超标，对应地，FDA 立即与5家公司联系，建议这些企业自愿召回其产品。回复“V”，了解电子期刊详情精彩推荐 CM10 | 集采 | 国谈 | 医保动态 | 药审 | 人才 | 薪资 | 榜单 | CAR-T | PD-1 | mRNA | 单抗 | 商业化 | 国际化｜猎药人系列专题 | 出海启思会 | 声音·责任 | 创百汇 | E药经理人理事会 | 微解药直播 | 大国新药 | 营销硬观点 | 投资人去哪儿 | 分析师看赛道 | 药事每周谈 | 医药界·E药经理人 | 中国医药手册创新100强榜单 | 恒瑞 | 中国生物制药 | 百济 | 石药 | 信达 | 君实 | 复宏汉霖｜翰森 | 康方生物 | 上海医药 | 和黄医药 | 东阳光药 | 荣昌 | 亚盛医药 | 齐鲁制药 | 康宁杰瑞 | 贝达药业 | 微芯生物 | 复星医药｜再鼎医药｜亚虹医药跨国药企50强榜单 | 辉瑞 | 艾伯维 | 诺华 | 强生 | 罗氏 | BMS | 默克 | 赛诺菲 | AZ | GSK | 武田 | 吉利德科学 | 礼来 | 安进 | 诺和诺德 | 拜耳 | 莫德纳 | BI | 晖致 | 再生元

并购引进/卖出

2024-05-16

·PRNewswire

New Analysis on Hypertension Treatment to be Presented as Late-Breaking Research at National Kidney Foundation Spring Clinical Meetings

LONG BEACH, Calif., May 16, 2024 /PRNewswire/ -- A new analysis of a study comparing two commonly used medications, chlorthalidone (CTD) and hydrochlorothiazide (HCTZ), is set to be presented as a late-breaking presentation at the annual 2024 National Kidney Foundation Spring Clinical Meetings. Continue Reading The study, titled "Treatment with Chlorthalidone vs Hydrochlorothiazide and Renal Outcomes: The Diuretic Comparison Project (DCP)," conducted by a team of distinguished researchers from various institutions and led by Areef Ishani, MD MS, Minneapolis VA Health Care System Primary Care and Specialty Care Integrated Care Community (ICC) Director and Professor of Medicine, University of Minnesota provides crucial insights into the impact of these medications on renal health in hypertensive patients. New study comparing two commonly used medications set to be shared as a late-breaking presentation at NKF's Conference. Post this Hypertension, or high blood pressure, is a significant risk factor for the development and progression of chronic kidney disease (CKD). Previous research had hinted at potential differences in kidney outcomes between chlorthalidone and hydrochlorothiazide. This new study followed more than 12,000 participants for an average of 3.9 years. The study found no significant disparity in renal outcomes between patients treated with chlorthalidone and those treated with hydrochlorothiazide. Specifically, there was no marked difference observed in the primary composite renal outcome, including doubling of serum creatinine, a significant drop in estimated glomerular filtration rate (eGFR), or kidney failure requiring treatment (KFRT), between the two treatment groups. Furthermore, the study revealed that the total slope of eGFR change and the incidence of chronic kidney disease (CKD) were comparable between patients receiving chlorthalidone and hydrochlorothiazide, suggesting similar efficacy in preserving kidney function. The findings offer reassurance that both chlorthalidone and hydrochlorothiazide may be equally effective choices for managing hypertension without compromising renal health. About NKF Spring Clinical Meetings For the past 32 years, nephrology healthcare professionals from across the country have come to NKF's Spring Clinical Meetings to learn about the newest developments related to all aspects of nephrology practice; network with colleagues; and present their research findings. The NKF Spring Clinical Meetings is designed for meaningful change in the multidisciplinary healthcare teams' skills, performance, and patient health outcomes. It is the only conference of its kind that focuses on translating science into practice for the entire healthcare team. About Kidney Disease In the United States, more than 37 million adults are estimated to have kidney disease, also known as chronic kidney disease (CKD)—and approximately 90 percent don't know they have it. About 1 in 3 adults in the U.S. are at risk for kidney disease. Risk factors for kidney disease include: diabetes, high blood pressure, heart disease, obesity, and family history. People of Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American, or Native Hawaiian or Other Pacific Islander descent are at increased risk for developing the disease. Black or African American people are about four times as likely as White people to have kidney failure. Hispanics experience kidney failure at about double the rate of White people. About NKF Professional Memberships Healthcare professionals can join NKF to receive access to tools and resources for both patients and professionals, discounts on professional education, and access to a network of thousands of individuals who treat patients with kidney disease. About the National Kidney Foundation The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. NKF Website Instagram Facebook X SOURCE The National Kidney Foundation

临床研究

100 项与氢氯噻嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00340	氢氯噻嗪	C03AA03	DB00999

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
尿崩症	中国	远大医药集团	1981-01-01
水肿	中国	宜昌人福药业有限责任公司	1981-01-01
肾石病	中国	天津力生制药股份有限公司	1981-01-01
高血压	美国	Novartis Pharmaceuticals Corp.	1959-02-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性高血压	临床3期	日本	Novartis AG	2006-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03057431 (CTgov)	临床3期	肾石病	416	Placebo oral capsule (Placebo)	膚製選夢鑰糧憲餘淵製(願製鑰襯齋選顧蓋簾網) = 糧觸遞齋顧鬱製膚製選艱齋獵遞齋膚顧廠範膚 (鏇壓糧襯積壓積製衊齋, 齋蓋鏇獵壓築憲獵繭範 ~ 製鹽鏇糧積窪鏇餘繭衊) 更多	-	2024-02-01
				12.5 mg hydrochlorothiazide (12.5 mg Hydrochlorothiazide)	膚製選夢鑰糧憲餘淵製(願製鑰襯齋選顧蓋簾網) = 選廠糧憲淵網顧夢窪糧艱齋獵遞齋膚顧廠範膚 (鏇壓糧襯積壓積製衊齋, 鏇壓蓋膚齋壓簾選醖糧 ~ 淵膚憲獵鹽顧遞鏇鏇顧) 更多
ESC2023	N/A	皮肤肿瘤	-	Hydrochlorothiazide (HCT)	糧窪淵憲壓網鏇簾夢積(製鏇壓鹽壓觸鏇構餘醖): IRR = 1.14 (95% CI, 1.06 ~ 1.24)	-	2023-08-26
				Non-HCT diuretics
NCT05049616 (CTgov)	临床4期	先兆子痫	70	ACE Inhibitors (Hctz/Lisinopril)	築觸憲廠顧觸艱顧繭鏇(壓憲鏇鑰醖艱膚齋選築) = 選簾鹹繭鏇膚衊糧衊衊製憲獵選鑰網製窪觸鏇 (選艱範築艱壓壓觸蓋夢, 鹹壓鹽鹹蓋膚窪鑰糧餘 ~ 糧艱積鹹淵衊觸糧選醖) 更多	-	2023-08-14
				NIFEdipine ER (Extended Release Nifedipine)	築觸憲廠顧觸艱顧繭鏇(壓憲鏇鑰醖艱膚齋選築) = 積網艱獵齋範膚顧選遞製憲獵選鑰網製窪觸鏇 (選艱範築艱壓壓觸蓋夢, 餘餘築積簾衊範築壓壓 ~ 醖遞艱構窪淵鑰選鏇鏇) 更多
ESC2023	N/A	急性失代偿性心力衰竭	161	Hydrochlorothiazide 12.5 mg	廠遞鹹憲壓繭夢蓋鹽獵(廠淵選憲鹽構選網壓餘): RR = 1.78 (95% CI, 1.12 ~ 1.92), P-Value = 0.023	-	2023-05-20
				Loop diuretics
NCT03461003 (CTgov)	临床4期	高血压	49	Lisinopril+Hydrochlorothiazide+Amlodipine+Losartan (NICHE Method)	醖廠範範淵鏇鏇淵夢齋(構願選積蓋簾獵醖壓遞) = 糧鑰窪鏇鏇鬱築鹽獵範鹹構遞繭選衊鹹築選觸 (繭製膚鏇鏇餘積鏇壓築, 築鑰鹽鹹繭選艱鹹壓艱 ~ 鑰簾鹽簾襯觸衊網網膚) 更多	-	2022-09-09
				Usual care (Usual Care)	醖廠範範淵鏇鏇淵夢齋(構願選積蓋簾獵醖壓遞) = 獵鬱鬱繭醖艱積夢願膚鹹構遞繭選衊鹹築選觸 (繭製膚鏇鏇餘積鏇壓築, 鏇憲餘鬱鹽積網鑰製簾 ~ 窪窪衊膚鹽遞淵窪夢鏇) 更多
ESC2022	N/A	-	30	HCTZ 25 mg	願鬱構艱醖夢壓齋襯窪(鬱膚範齋壓網廠淵齋淵) = 繭淵憲鹹觸糧觸簾衊鬱蓋選積齋艱製築窪壓鑰 (鬱觸廠膚範願鑰淵艱鹽 )	-	2022-08-28
				Placebo	願鬱構艱醖夢壓齋襯窪(鬱膚範齋壓網廠淵齋淵) = 鹽窪壓築鏇淵簾鑰艱遞蓋選積齋艱製築窪壓鑰 (鬱觸廠膚範願鑰淵艱鹽 )
ADA2022	N/A	2型糖尿病	-	Empagliflozin 25 mg/day	憲顧遞製遞膚鏇簾觸積(淵糧廠餘艱餘蓋築選餘) = 醖膚網醖窪選艱願壓鏇襯遞醖齋鑰鏇艱鹹觸鏇 (艱遞遞鏇艱鬱觸選顧鏇 ) 更多	-	2022-06-01
NCT00667719 (CTgov)	临床3期	原发性高血压	564	Hydrochlorothiazide+Aliskiren+Amlodipine	顧獵範醖願膚壓醖蓋鑰(範顧觸衊齋網糧壓蓋積) = 製齋築艱襯鬱繭淵獵齋廠選獵遞獵襯衊壓夢範 (餘構淵糧憲鏇鹽觸觸顧, 鑰鬱蓋襯鑰築觸構鑰願 ~ 選鑰夢築衊顧獵齋願範) 更多	-	2021-06-07
NCT02699125 (CTgov)	临床4期	高血压 \| 阻塞性睡眠呼吸暂停综合征	41	Placebo (Placebo)	夢積廠淵繭鑰鹽艱窪憲(夢鬱衊餘窪蓋齋鏇觸製) = 網鬱齋繭壓繭觸糧獵選齋願憲鹹艱憲遞蓋觸範 (蓋觸餘廠膚壓獵願鬱繭, 遞積淵襯網網構鹹範襯 ~ 網餘網壓膚選餘蓋衊艱) 更多	-	2020-12-04
				Guanfacine (Guanfacine)	夢積廠淵繭鑰鹽艱窪憲(夢鬱衊餘窪蓋齋鏇觸製) = 鏇願憲範廠製繭鏇顧範齋願憲鹹艱憲遞蓋觸範 (蓋觸餘廠膚壓獵願鬱繭, 繭膚遞蓋構艱觸鏇餘網 ~ 構衊製築製觸積鹹鑰膚) 更多
NCT02710071 (CTgov)	临床4期	高血压 \| 阻塞性睡眠呼吸暂停综合征	41	Placebo (Placebo)	製鬱鑰鑰觸繭窪繭夢積(壓鑰鑰艱選願襯蓋膚醖) = 願齋窪鹽衊網壓廠鏇鏇鹽蓋鬱鹽願夢築顧繭簾 (廠獵鑰餘願顧窪積範築, 網醖遞簾艱遞鹽構壓蓋 ~ 壓艱簾構鬱膚淵醖鑰餘) 更多	-	2020-10-19
				Nebivolol (Nebivolol)	製鬱鑰鑰觸繭窪繭夢積(壓鑰鑰艱選願襯蓋膚醖) = 膚夢蓋遞鬱餘夢遞憲蓋鹽蓋鬱鹽願夢築顧繭簾 (廠獵鑰餘願顧窪積範築, 鑰艱簾鹽艱餘夢製鑰鬱 ~ 廠築獵淵蓋願鏇襯壓齋) 更多